黄地养阴颗粒联合夫西地酸乳膏及阿达帕林凝胶治疗寻常型痤疮的疗效观察

目的探讨黄地养阴颗粒联合夫西地酸乳膏及阿达帕林凝胶治疗寻常型痤疮的疗效及不良反应。方法随机分为3组,每组35例。A组为夫西地酸乳膏+阿达帕林凝胶组;B组为黄地养阴颗粒组;C组为夫西地酸乳膏+阿达帕林凝胶+黄地养阴颗粒组。A组为白天涂2%夫西地酸乳膏,晚上涂0.1%阿达帕林凝胶;B组为黄地养阴颗粒2次/d;C组为2%夫西地酸乳膏+0.1%阿达帕林凝胶+黄地养阴颗粒。疗程均为8周,每2周复诊1次。观察记录疗效指标及不良反应。结果经过8周治疗后,A组、B组、C组有效率分别为68.6%、71.4%、91.4%。A、B组疗效差异无统计学意义,C组优于A组及B组。治疗中A、C组少数病人出现面部红斑、脱屑,B、C组少数出现轻度腹泻,随着治疗时间的延长逐渐消失,未影响继续治疗。结论 3药联合应用,对轻、中度痤疮及炎症、非炎症皮损均能发挥更好的作用。即可减少全身用药的不良反应,同时也增强了病人的依从性,从而达到提高疗效的目的。     

过氧苯甲酰联合夫西地酸及阿达帕林治疗寻常型痤疮疗效观察

目的探讨过氧苯甲酰联合夫西地酸及阿达帕林治疗寻常型痤疮的疗效及安全性。方法寻常型痤疮210例,随机分为三组,每组70例,治疗组为过氧苯甲酰+夫西地酸+阿达帕林组;对照A组为夫西地酸+阿达帕林组;对照B组为过氧苯甲酰组+阿达帕林组。每2周复诊1次,观察不良反应,治疗8周后,观察疗效。结果治疗结束后,治疗组有效率88.6%,对照A组有效率68.6%,对照B组有效率71.4%。治疗组与对照A组差异有统计学意义(P=0.035,P0.05);治疗组与对照B组差异有统计学意义(P=0.023,P0.05);对照A、B两组差异无统计学意义(P=0.44,P0.05)。治疗过程中,三组均无明显不良反应。结论过氧苯甲酰联合夫西地酸及阿达帕林治疗轻中度寻常型痤疮疗效显著,不良反应少。     

夫西地酸联合阿达帕林凝胶治疗轻中度寻常型痤疮疗效观察

目的:观察夫西地酸联合阿达帕林凝胶治疗轻中度寻常型痤疮的临床疗效和安全性。方法:将100例Ⅰ~Ⅱ级寻常型痤疮患者随机分为两组,实验组56例予2%夫西地酸乳膏2次/日涂患处,对照组44例予1%克林霉素凝胶2次/日涂患处,两组均每晚外涂0.1%阿达帕林凝胶1次,2周为1个疗程,共4周。比较两组疗效。结果:实验组痊愈31例,显效19例,有效率为89.3%;对照组痊愈12例,显效16例,有效率为63.6%。两组有效率比较,差异有统计学意义(χ~2=8.01,P<0.05)。结论:夫西地酸联合阿达帕林凝胶治疗轻中度寻常型痤疮安全有效,值得临床推广应用。     

夫西地酸乳膏联合多磺酸黏多糖乳膏治疗寻常痤疮疗效观察

目的观察夫西地酸乳膏联合多磺酸黏多糖乳膏治疗轻中度寻常痤疮的临床疗效及不良反应。方法采用随机方法将123例轻中度寻常痤疮患者分为2组,试验组联合应用夫西地酸乳膏和多磺酸黏多糖乳膏,对照组用阿达帕林凝胶,疗程6周,观察2组患者的治疗结果和不良反应。结果试验组有效率85.91%,对照组有效率71.15%,试验组有效率高于对照组,差异有统计学意义(P0.05),2组均未见明显不良反应发生。结论夫西地酸乳膏联合多磺酸黏多糖乳膏治疗寻常痤疮临床疗效确切,安全性高。     

复方多粘菌素B软膏联合阿达帕林凝胶治疗中度痤疮疗效观察

目的观察复方多粘菌素B软膏联合阿达帕林凝胶治疗寻常型痤疮的疗效和安全性。方法将101例中度痤疮患者随机分为两组,治疗组55例采用复方多粘菌素B软膏联合阿达帕林凝胶治疗,阿达帕林凝胶每晚1次,复方多粘菌素B软膏2次/d,疗程为4周;对照组46例,每晚1次外用阿达帕林凝胶,莫匹罗星乳膏2次/d,连续4周为一个疗程。结果治疗组和对照组有效率分别为83.6%和65.2%,有效率存在明显差异(P0.05)。治疗组不良反应明显少于对照组。结论复方多粘菌素B软膏联合阿达帕林凝胶治疗寻常型痤疮可明显提高疗效,减少不良反应,值得临床推广。     

夫西地酸乳膏联合阿达帕林凝胶治疗寻常痤疮效果观察

目的观察夫西地酸乳膏联合阿达帕林凝胶治疗寻常痤疮的临床效果。方法选取2017年3月至2018年3月在我院接受治疗的86例痤疮患者作为研究对象,随机分为对照组和观察组,每组各43例。对照组单用阿达帕林凝胶治疗,观察组在此基础上联合夫西地酸乳膏进行治疗。比较两组治疗前后皮疹数、临床疗效及安全性。结果治疗前两组患者皮疹计数比较,差异无统计学意义(P 0.05);治疗8周后,观察组炎性皮疹计数和非炎性皮计疹数均低于对照组,差异有统计学意义(P 0.05);观察组总有效率高于对照组,差异有统计学意义(P 0.05);两组不良反应发生率相比,差异无统计学意义(P 0.05)。结论夫西地酸乳膏联合阿达帕林凝胶治疗寻常痤疮患者临床疗效显著,可有效改善患者症状,无明显不良反应,具有较高的安全性。     

红蓝光联合阿达帕林治疗轻中度痤疮临床疗效观察

目的探讨红蓝光照射联合0.1%阿达帕林凝胶治疗痤疮的临床疗效和安全性。方法将161例轻、中度痤疮患者分为三组,0.1%阿达帕林凝胶联合红蓝光照射治疗组,仅用红蓝光照射治疗组,仅外用0.1%阿达帕林凝胶治疗组。按皮损治疗前后减少率来判定疗效。结果三组有效率分别为93.55%、80.49%、65.52%。结论红蓝光联合0.1%阿达帕林凝胶治疗面部轻、中度痤疮安全有效。     

0.1%阿达帕林凝胶和2%夫西地酸乳膏联合外用治疗寻常痤疮疗效观察

目的探讨痤疮的有效治疗方法。方法治疗组30例采用阿达帕林凝胶和夫西地酸乳膏联合治疗,对照组28例采用夫西地酸乳膏治疗,8周后结束观察并总结。结果治疗组有效率86.7%,对照组有效率64.3%,两组比较差异有显著性(P<0.05)。结论阿达帕林凝胶和夫西地酸乳膏联合治疗痤疮疗效满意。     

夫西地酸乳膏治疗寻常痤疮临床疗效观察

目的评价2％夫西地酸乳膏治疗寻常痤疮的临床疗效及安全性。方法将100例I～II级寻常痤疮患者随机分为两组，一组50例予2％夫西地酸乳膏2次／d涂患处，另一组50例采用红霉素软膏外用，2次／d，14d为1个疗程，共观察28d。结果2％夫西地酸乳膏治疗寻常痤疮治愈率46％，有效率86％，不良反应症状轻微且短暂。结论2％夫西地酸乳膏治疗寻常痤疮疗效肯定且较为安全。     

自制复方烟酰胺沙星软膏联合阿达帕林凝胶治疗寻常痤疮的疗效观察

目的:观察自制复方烟酰胺沙星软膏联合0.1%阿达帕林凝胶治疗寻常痤疮的临床疗效。方法:将按入选标准入选的90例寻常痤疮患者随机分为2组,每组45例。治疗组每天早晨、中午各点涂复方烟酰胺沙星软膏1次,晚上薄涂0.1%阿达帕林凝胶1次;对照组每晚薄涂0.1%阿达帕林凝胶1次,疗程均为8周,治疗结束后观察疗效并进行比较。结果:治疗8周疗程结束时治疗组有效率为91.1%,明显高于对照组(71.1%),差异有统计学意义(2=4.66,P0.05)。结论:自制复方烟酰胺沙星软膏联合0.1%阿达帕林凝胶治疗Ⅰ~Ⅱ级轻中度寻常痤疮,可协同作用于炎症性和非炎症性皮损,疗效显著。     

异维A酸红霉素凝胶治疗寻常痤疮的多中心随机对照临床研究

目的 比较异维A酸红霉素凝胶与阿达帕林凝胶治疗轻中度寻常痤疮的疗效和安全性。方法 多中心、开放、随机、平行对照研究。按照中国痤疮治疗指南痤疮严重程度标准入选轻、中度（Ⅰ ~ Ⅲ级）寻常痤疮患者192例,纳入疗效分析169例,安全性分析190例。试验组86例,外用异维A酸红霉素凝胶;对照组83例,外用阿达帕林凝胶,均为每晚1次,共用药6周。在基线、治疗2、4和6周时分别记录患者白头粉刺、黑头粉刺、炎性丘疹、脓疱数,评价各时间点患者痤疮严重程度,同时记录皮肤局部耐受性以及其他不良反应。结果 随着治疗时间延长,两组的有效率逐渐提高,总体病情严重程度改善。在治疗6周时,试验组总有效率为51.16%,对照组为40.96%,两组差异无统计学意义（P > 0.05）;但在治疗4周及6周时,试验组患者脓疱及炎性皮损的疗效优于对照组（P < 0.05）,同时试验组痤疮分级较对照组低（P < 0.01）。两组不良反应类似,均表现为局部刺激,可耐受。结论 异维A酸红霉素凝胶治疗轻、中度寻常痤疮总有效率与阿达帕林凝胶类似,对于炎性损害疗效优于阿达帕林凝胶,并且对患者总体严重程度降低更快。     

Randomised,controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris

BACKGROUND: Previous clinical trials have shown that adapalene gel produces less irritation than tretinoin gels and tretinoin 0.025% cream. Short term results have shown that adapalene is less irritating than tretinoin gels and creams. This study is the first to compare the 0.1% formulation of adapalene gel with the 0.05% strength of tretinoin cream in a formal clinical trial. OBJECTIVE: To investigate the efficacy and tolerability of adapalene gel 0.1% compared with tretinoin cream 0.05% in patients with mild-to-moderate acne vulgaris. METHODS: Ten-week, multicentre, randomised, investigator-masked, active-controlled, parallel group study in 409 patients with acne vulgaris. RESULTS: Adapalene gel 0.1% demonstrated equivalent efficacy in reduction of acne lesion counts and global improvement of acne severity over 10 weeks' treatment and was significantly better tolerated than tretinoin cream 0.05% in terms of erythema, dryness, desquamation and stinging/burning. CONCLUSION: Adapalene gel 0.1% showed equivalent efficacy and was significantly better tolerated than tretinoin cream 0.05% in patients with mild-to-moderate acne vulgaris.     

0.1%阿达帕林凝胶预防和减轻寻常痤疮复发的多中心随机对照临床试验

目的评价0.1%阿达帕林凝胶维持治疗对于预防和减轻寻常痤疮复发的作用.方法采用多中心、区组随机、开放、对照的方法,共入选患者246例,均为经过阿达帕林和克林霉素(特丽仙)联合治疗或特丽仙单独治疗获得有效(改善≥25%)的寻常痤疮患者,随机分为两组,一组外用0.1%阿达帕林凝胶,另一组不用药,均观察12周.结果239例患者完成治疗和观察,阿达帕林组121例,对照组118例.治疗4周后阿达帕林组炎性皮损数的减少显著优于对照组(P＜0.05),并维持至12周;治疗8周后阿达帕林组皮损总数和非炎性皮损数的减少也显著优于对照组(P＜0.01),并维持至12周.治疗结束后,阿达帕林组总体改善率为66.9%,对照组为4.2%(P＜0.01);阿达帕林组总复发率为4.1%,对照组为83.9%;两组间差异有显著性(P＜0.01).阿达帕林组有个别病例有轻度局部刺激反应,两组间不良反应差异无显著性(P＜0.05).结论阿达帕林凝胶可有效地治疗寻常痤疮,并维持治疗效果,且不增加局部刺激反应,对于减少病情复发具有显著效果.     

阿达帕林凝胶治疗寻常痤疮10年回顾

目的 总结阿达帕林凝胶治疗寻常痤疮的临床文献,为临床合理用药提供参考。方法 对阿达帕林凝胶上市10年来国内有关治疗寻常痤疮的疗效及安全性观察的中文文献进行整理和分析。结果 联合用药组疗效高于单用药物组,阿达帕林凝胶组疗效与其他维A酸类药物疗效相当,但高于其他痤疮药物组,不良反应低于其他药物。结论 阿达帕林凝胶治疗轻中度痤疮安全、有效,可单独或联合用药,还可作为维持治疗。     

Spotlight on Adapalene in Acne Vulgaris

Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris. In clinical trials, 0.1% adapalene gel has proved to be effective in this indication and was as effective as 0.025% tretinoin gel, 0.1% tretinoin microsphere gel, 0.05% tretinoin cream and 0.1% tazarotene gel once every two days; however, the drug was less effective than once-daily 0.1% tazarotene gel. It can be used alone in mild acne or in combination with antimicrobials in inflammatory acne and has proved efficacious as maintenance treatment. Adapalene has a rapid onset of action and a particularly favorable tolerability profile compared with other retinoids. These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris.     

异维A酸红霉素凝胶治疗轻、中度寻常性痤疮临床观察

目的观察异维A酸红霉素凝胶治疗轻、中度寻常性痤疮的疗效和安全性。方法采用单盲随机阳性药物对照的临床试验。治疗组采用异维A酸红霉素凝胶,每晚外用1次;对照组采用他扎罗汀乳膏,每晚外用1次,连续应用56天。结果治疗后,两组皮损数目均减少。治疗组和对照组有效率分别为80.56%和65.71%,差异有统计学意义(P<0.05);两组不良反应发生率分别为13.89%和21.34%,差异无统计学意义(P>0.05)。结论异维A酸红霉素凝胶治疗轻、中度寻常性痤疮安全有效,值得临床推广应用。     

Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline

Topical retinoids are often recommended for preventing acne recurrence, but there are relatively few well-controlled maintenance studies published. The objective of the present study was to assess the maintenance effect of adapalene gel 0.1% relative to gel vehicle in subjects successfully treated in a previous 12-week adapalene-lymecycline 300 mg combination therapy study. This was a multicentre, investigator-blind, randomised, controlled study in 19 European centres. A total of 136 subjects with moderate to moderately-severe acne vulgaris who showed at least moderate improvement from baseline when treated with either adapalene plus lymecycline or lymecycline plus gel vehicle in a previous 12 week study were included. Subjects were randomised to receive adapalene gel 0.1% or vehicle once-daily for 12 weeks. Efficacy and safety criteria included maintenance rate, percent reduction in lesion counts (total, inflammatory, non inflammatory), global severity assessment, cutaneous tolerability, and adverse events. Adapalene provided better results relative to gel vehicle for all efficacy assessments. The maintenance rate for total lesions was 84.7% vs. 63.5% (P = 0.0049) with adapalene and the vehicle, respectively. Adapalene was safe and well tolerated in this study. This study demonstrates a clinical benefit of continued treatment with adapalene gel 0.1% as a maintenance therapy for acne.     

Adapalene gel 0.1% vs ketoconazole cream 2% and their combination in treatment of pityriasis versicolor: A randomized clinical study

Pityriasis versicolor (PV) is a chronic superficial fungal infection. Management using azole drugs leads to drug resistance. The present study aimed to compare the clinical outcome of 0.1% adapalene gel vs 2% ketoconazole cream and their combination in PV. This randomized double‐blinded study was conducted on 90 PV patients divided into three equal groups. GI was treated with topical ketoconazole 2% cream twice daily and placebo, GII was treated with topical 0.1% adapalene gel twice daily and placebo and GIII was treated with topical combination of 0.1% adapalene gel (at night) and ketoconazole 2% cream (in the morning). All patients received medications for 4 weeks. Evaluation was done at 2 and 4 weeks and included clinical assessment, laboratory assessment, and patient satisfaction. We found that after 4 weeks of treatment, all groups showed significant improvement. There was better response in GIII in terms of lower rate of positive potassium hydroxide staining, higher rate of significantly improved cases and higher rate of well‐satisfied patients. However, the difference fell short of statistical significance. We concluded that a combination of adapalene gel and ketoconazole cream is very effective in treatment of PV with no or mild side effects.     

Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel

Adapalene 0.1%/benzoyl peroxide 2.5% gel (Epiduo?, Tactuo?) is the only fixed-dose combination product available that combines a topical retinoid with benzoyl peroxide; it targets three of the four main pathophysiologic factors in acne. This article reviews the therapeutic efficacy and tolerability of topical adapalene 0.1%/benzoyl peroxide 2.5% gel in the treatment of patients aged ≥ 12 years with acne vulgaris, as well as summarizing its pharmacologic properties. In three 12-week trials in patients aged ≥12 years with moderate acne, success rates were significantly higher with adapalene 0.1%/benzoyl peroxide 2.5% gel than with adapalene 0.1% gel or benzoyl peroxide 2.5% gel alone, and combination therapy had an earlier onset of action. In addition, significantly greater reductions in total, inflammatory, and noninflammatory lesion counts were seen in patients receiving adapalene 0.1%/benzoyl peroxide 2.5% gel than in those receiving adapalene 0.1% gel or benzoyl peroxide 2.5% gel alone. Adapalene 0.1%/benzoyl peroxide 2.5% gel did not significantly differ from clindamycin 1%/benzoyl peroxide 5% gel in terms of the reduction in the inflammatory, noninflammatory, or total lesion counts in patients with mild to moderate acne, according to the results of a 12-week trial. Twelve-week studies showed that topical adapalene 0.1%/benzoyl peroxide 2.5% gel in combination with oral lymecycline was more effective than oral lymecycline alone in patients with moderate to severe acne, and topical adapalene 0.1%/benzoyl peroxide 2.5% gel in combination with oral doxycycline hyclate was more effective than oral doxycycline hyclate alone in patients with severe acne. In patients with severe acne who responded to 12 weeks’ therapy with topical adapalene 0.1%/benzoyl peroxide 2.5% gel plus oral doxycycline hyclate or oral doxycycline hyclate alone, an additional 6 months’ therapy with adapalene 0.1%/benzoyl peroxide 2.5% gel was more effective than vehicle gel at maintaining response, with further improvement seen in adapalene 0.1%/benzoyl peroxide 2.5% gel recipients. A noncomparative study also demonstrated the efficacy of 12 months’ therapy with adapalene 0.1%/benzoyl peroxide 2.5% gel in patients with acne vulgaris. Topical adapalene 0.1%/benzoyl peroxide 2.5% gel was generally well tolerated in patients with acne. In 12-week trials, the most commonly occurring treatment-related adverse events included erythema, scaling, dryness, and stinging/burning; these dermatologic treatment-related adverse events were usually of mild to moderate severity, occurred early in the course of treatment, and resolved without residual effects. Topical adapalene 0.1%/benzoyl peroxide 2.5% gel was generally well tolerated in the longer term, with dry skin being the most commonly occurring treatment-related adverse event over 12 months of treatment. In conclusion, adapalene 0.1%/benzoyl peroxide 2.5% gel is a valuable agent for the first-line treatment of acne vulgaris.